---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-005951"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2025-03-03T23:59:59+00:00"
generated_at: "2026-05-25T17:59:11.079473+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Monopar appoints Quan Vu as CFO, replacing Karthik Radhakrishnan

## Summary
- Karthik Radhakrishnan's employment terminated Feb 28, 2025; he ceased serving as CFO, principal financial and accounting officer.
- Quan Vu appointed CFO, principal accounting and financial officer effective March 3, 2025.
- Vu brings over 20 years of experience, most recently as Venture Partner at ZhongMei Capital, previously CFO/COO at Ocugen and 180 Life Sciences.
- Vu receives annual salary $350,000, target bonus up to 35% of base salary, and stock options for 25,000 shares vesting over 4 years.
- Options granted under Monopar's 2016 Stock Incentive Plan; no related party transactions reported.

## SEC filing metadata
- accession: 0001437749-25-005951
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2025-03-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000143774925005951/0001437749-25-005951-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000143774925005951/mnpr20250228_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-005951
- JSON: https://secwatch.observer/filing/0001437749-25-005951.json
- Plain text: https://secwatch.observer/filing/0001437749-25-005951.txt

## Key facts
- Executive change
  Karthik Radhakrishnan was terminated as Chief Financial Officer at Monopar Therapeutics.
  - Action: terminated
  - Role: Chief Financial Officer
  source text: On February 28, 2025, Karthik Radhakrishnan’s employment with Monopar Therapeutics Inc. (the “Company” or “Monopar”) terminated.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645469/000143774925005951/0001437749-25-005951-index.htm
- Executive change
  Quan Vu was appointed as Chief Financial Officer at Monopar Therapeutics.
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On February 27, 2025, the Company’s Board of Directors appointed Quan Vu, age 53, to succeed Mr. Radhakrishnan as Monopar’s Chief Financial Officer, principal accounting officer and principal financial officer effective March 3, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645469/000143774925005951/0001437749-25-005951-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.